We were first focused on EGFR, because it was recently identified by the biomarker study after ACTS-GC trial; EGFR was proven to be a prognostic marker in stage II/III gastric cancer patients who underwent postoperative S-1 adjuvant therapy differently from HER2 23 as well as previous other study 24. This evidence concerns the gene EGFR and gastric cancer.